Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Roche Pegasys Hep C Monotherapy Launch Expected Before Combo Approval

  • News

Executive Summary

Roche Pegasys hepatitis C monotherapy could launch as early as October, two months before the expected approval of the combination pegylated interferon alfa-2a/ribavirin product

You may also be interested in...



Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples

Roche's Pegasys has a wholesale acquisition cost of $291 for one week of the hepatitis C therapy

Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples

Roche's Pegasys has a wholesale acquisition cost of $291 for one week of the hepatitis C therapy

Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment

Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS040349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By